ADDvise Group’s long term financial targets

11-09-2017   Regulatory press release

The board of directors of ADDvise Group has adopted long term financial targets. The strategy to focus on high revenue growth based on a combination of acquisitions and organic growth remains. Profitable revenue growth combined with reduced net debt to EBITDA is an overall target. Given time dividend to ADDvise Group’s shareholders will be added.

ADDvise Group’s long term financial targets is not to be mistaken for an annual forecast. The financial targets should be seen as an ambition from the board and CEO. The targets will be achieved both by acquisitions and organic growth. The targets are categorized within four areas: growth, profitability, capital structure and dividend.

ADDvise Group’s long term financial targets as of September 11th 2017 are:

Revenue growth: Annual growth in revenue shall exceed 20%. Growth will be both acquired and organic.

Profitability: EBITDA-margin shall reach 10%

Capital structure: Net interest-bearing debt in relation to EBITDA shall not exceed 3,0 times.

Dividend: 25 % of previous year EBT, excluding revaluation of pending earn outs, shall constitute shareholders’ dividend.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 


Important information:
 

This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on September 11th, 2017 at 09:00 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise acquires Seebreath AB

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…

Interim report January 1 – March 31 2022

Regulatory

January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…

ADDvise acquires Surplus Diabetics, Inc.

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Surplus Diabetics, Inc. (“Surplus Diabetics”) regarding the acquisition of all the outstanding shares of Surplus Diabetics in accordance with the letter of intent communicated via a press release dated January 17, 2022. Closing of the acquisition takes place today. Surplus…